Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 360 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Cream Clear all
Completed Phase 4 Interventional Results available

CeraVe Diabetes Mellitus

NCT04724967
View directory record Official record
Conditions
Diabetes Complications
Interventions
CeraVe Hydrating Cleanser, CeraVe Moisturizing Cream
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules

NCT02765763
View directory record Official record
Conditions
Skin Aging, Photoaging of Skin
Interventions
2-Minute Reveal Masque, 24/7 Barrier Repair Cream, 8-in-1 BioSerum, Null Formula 2-Minute Reveal Masque, Null Formula 24/7 Barrier Repair Cream, Null Formula 8-in-1 BioSerum
Drug
Lead sponsor
Advanced Dermatology
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincolnshire, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 21, 2026, 8:30 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00829049
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Adapalene
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

NCT01149876
View directory record Official record
Conditions
Hyperpigmentation
Interventions
Nu Skin Product, Cosmetic instrument, Tretinoin cream 0.05, CeraVe moisturizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Not applicable Interventional

Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions

NCT04169438
View directory record Official record
Conditions
Wound Heal, Scar, Keloid, Surgical Wound
Interventions
Vehicle Cream Base Emulsion Moisturizer + Petrolatum, FS2 Emulsion Moisturizer + Petrolatum
Other
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 21, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX

NCT01692626
View directory record Official record
Conditions
Rash
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

NCT05089708
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream, Trifarotene Vehicle Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 35 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Fountain Valley, California • Fremont, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 4 Interventional

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

NCT06673654
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy

NCT04173247
View directory record Official record
Conditions
Head and Neck Cancer, Radiation Dermatitis
Interventions
KeraStat Cream, Routine Skin Care - Commercially Available Agents
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

NCT01137032
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
Pandel Cream 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

NCT04856904
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream, Trifarotene Vehicle Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
17 Years to 35 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

NCT05635838
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

NCT04530344
View directory record Official record
Conditions
Vitiligo
Interventions
ruxolitinib, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

NCT03892564
View directory record Official record
Conditions
Phototoxicity
Interventions
MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 2Phase 3 Interventional

Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin

NCT07084116
View directory record Official record
Conditions
Skin Tear, Solar Purpura, Dermatoporosis
Interventions
Tretinoin 0.1% cream, Bland cream (non-drug)
Drug
Lead sponsor
James Thomas Pathoulas
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 8:30 AM EDT
Terminated Not applicable Interventional Results available

Hydrogel Patch for the Treatment of Eczema

NCT00924508
View directory record Official record
Conditions
Eczema
Interventions
hydrogel patch, Triamcinolone (TAC) 0.1% cream
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

NCT04531813
View directory record Official record
Conditions
Hypersensitivity
Interventions
Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Not applicable Interventional

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

NCT00705900
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
LCD, calcipotriol
Drug
Lead sponsor
NeoStrata Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

NCT02791308
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 90 Years
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 21, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02131324
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06 Cream, Clobetasol Propionate Cream 0.05%
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Glendale, Arizona • Mesa, Arizona • Encino, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 21, 2026, 8:30 AM EDT
Recruiting Phase 3 Interventional

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

NCT07335588
View directory record Official record
Conditions
Lichen Sclerosus
Interventions
Delgocitinib, Cream Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 8:30 AM EDT